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Several different prognostic systems are currently in use world-
wide to predict the outcome of patients with hepatocellular car-
cinoma. Some of them have been widely publicized [1,2] while
others have not been acknowledged by a wider audience so far
[3]. All of the systems currently in use, except for the TNM-sys-
tem, have taken care of the fact that prognosis in patients with
HCC is decided not only by the tumor burden but, to a very sig-
niﬁcant part, also by the degree of the underlying liver cirrhosis.
The oldest of the prognostic systems still in use today, the Okuda
system, has simply taken three parameters of the Child-Pugh
Score and supplemented it with a very crude estimation of the
tumor size on imaging, thereby deriving a very simple but also
for many patients today inaccurate three-stage prognostic system
[4]. In particular, Okuda staging is mostly helpful for estimating
the prognosis of the early as well as the most advanced stages
of disease, while leaving the majority of patients in the interme-
diate Okuda stage II with a very rough estimate of the survival,
which made it a system of very low practical value for the man-
agement of patients with HCC.
In their recently published manuscript, Huitzil-Melendez and
colleagues retrospectively compare the predictive power of seven
different prognostic systems with regards to the outcome of
patients with advanced stage HCC, destined to undergo medical
therapy for their disease [5]. Their conclusion after evaluating
TNM sixth edition, Okuda, BCLC, CLIP, CUPI, JIS, and GETCH in
187 eligible patients is that CLIP, CUPI, and GETCH were the most
informative systems, while BCLC and TNM lacked discriminatory
power in their patients. Looking at individual parameters, the
addition of performance status, AST, abdominal pain, and esoph-
ageal varices to CLIP would be able to improve its prognostic
accuracy even further. The general idea of the authors was to ﬁndJournal of Hepatology 20
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Several issues related to the manuscript have to be put into
perspective, which limit the validity of the conclusions drawn
by the authors. Besides severe technical shortcomings in the
acquisition of key parameters like calculating Child-Pugh score
retrospectively from chart review (with potentially severe inac-
curacies related to encephalopathy and also ascites) and CT/
MR-reading being performed by a medical oncologist and not a
radiologist, the authors are not doing themselves a favor by com-
paring apples with pears. TNM and BCLC are primarily staging
systems that were designed to guide treatment decisions and at
least BCLC fulﬁlls this task also formidably. The other systems
evaluated are true prognostic systems that do not give guidance
for the treatment, and not surprisingly, they do perform better for
this task. Furthermore, advanced stage HCC, as evaluated in this
manuscript, is almost synonymous with BCLC stage C and accord-
ingly, 85% of the patients included in this analysis fall within this
stage. It is almost ironic to select patients according to one stage
of a given classiﬁcation and then ask the very same system to
perform as a prognostic indicator within this stage. To evaluate
the performance of BCLC as a prognostic system, this would
require a more even inclusion of patients from different stages.
In fact, BCLC has been shown to be the best prognostic system
even in advanced patients, superior to CLIP, in a previous analysis
of seven prognostic systems [6].
While GETCH was able to deﬁne a subgroup with very good
prognosis, the overall performance favoured CLIP. A good perfor-
mance of CLIP in this evaluation does not come as a surprise, since
this has been demonstrated before [7]. This could be due to the
fact that CLIP is a good prognostic system but it could also be
due to the fact that the patients evaluated here are fairly evenly
distributed between the different stages of the CLIP system, which
is not true for all other systems evaluated in thismanuscript. CLIP-
score, which is derived from Child-Pugh stage, AFP, tumor mor-
phology, and portal vein status, can be improved by additional
variables. Two of those, performance status [6] and AST [8], are
well described prognostic factors in HCC, while abdominal pain
and the presence of varices are subjective or have not consistently
been shown to be of prognostic relevance. It can well be that these
parameters would be able to improve the prognostic accuracy of
the CLIP-score but prospective validation is warranted.
To conclude, no relevant new information is added through
this manuscript. We already knew that BCLC was a treatment
algorithm more than a prognostic system, TNM was a fairly use-
less system for both staging and evaluating prognosis in
advanced stage HCC, and that CLIP is quite good to derive prog-12 vol. 56 j 488–489
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nostic information even within the different strata of BCLC. Strat-
iﬁcation according to BCLC was able to deﬁne treatment relevant
prognostic groups and stage BCLC C has been shown to deﬁne a
group of HCC-patients with prognosis similar enough to allow
randomized trials to show a signiﬁcant effect of treatment
against the background of a highly variable outcome of the
underlying cirrhosis otherwise [9,10]. Improving the CLIP-score
by adding performance status and/or AST could be an interesting
concept but requires prospective validation in an independent
cohort of BCLC stage C patients.
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